• Gore Akash Balaji
• Guntapalle Jalba Balaji
• Bharde Vikrant Parmeshwar
• Gundare Santosh Rajendra

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to delivering treatment in cancer conditions and, in particular, has become a beacon of hope for patients suffering from hematological malignancies as well as solid tumors. The biological uniqueness of the therapy lies in the change brought about in T cells after genetic modification to display a CAR that recognizes the antigen specific for the tumor cell type, leading to the effective destruction of the malignant cells. Developments in CAR T-cell therapy started at the inception of the therapy, but major research today looks toward improving the CAR for design and function, exploration of more target antigens, and combination therapies. Clinical trials have demonstrated the very high efficacy of CAR T-cell treatment in B-cell acute lymphoblastic leukemia (B-ALL) or cytohistologically proven B-cell non-Hodgkin lymphomas (B-NHL) or chronic lymphocytic leukemia (CLL). Tumor Solid organs, especially breast, lung, and pancreas, are currently closely scrutinized by experts studying CAR T-cell potentials. Dr. Carlo Caligiuri, a pioneer at the forefront of this research presently conducted beyond the borders, has spoken of this prospect that could change treatment practices on tumor heterogeneity and antigen escape in traditional systems. The evidence so far suggests highly promising potentials of CAR T-cell therapy, but it has also been associated with severe side effects such as cytokine release syndrome (CRS), neurotoxicity, and B-cell aplasia. New generations of CAR that have increased specificity, affinity, and persistence are being developed to address these challenges. Moreover, the investigators are focusing their attention on tumor-specific neoantigens and rational combinations of CAR T-cell therapy with other immunotherapies, targeted therapies, and conventional treatments. Continues development put CAR T-cell therapy on the front line of reshaping the treatment landscape for cancer. Further research with clinical trials will support evidence giving clear light on its efficacy and safety.

CAR T-cell therapy, cancer treatment, chimeric antigen receptor, immunotherapy, hematological malignancies, solid tumors etc. Introduction

"CAR T-Cell Therapy : A New Horizon in Cancer Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 12, page no.h110-h123, December-2024, Available :http://www.jetir.org/papers/JETIR2412715.pdf

"CAR T-Cell Therapy : A New Horizon in Cancer Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 12, page no. pph110-h123, December-2024, Available at : http://www.jetir.org/papers/JETIR2412715.pdf